Comparative Pharmacology
Head-to-head clinical analysis: CHROMITOPE SODIUM versus DRAXIMAGE MDP 25.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CHROMITOPE SODIUM versus DRAXIMAGE MDP 25.
CHROMITOPE SODIUM vs DRAXIMAGE MDP-25
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Chromitope sodium (sodium chromate Cr-51) is a radioactive diagnostic agent. Chromium-51 is incorporated into red blood cells by binding to hemoglobin. Following intravenous injection, the labeled RBCs distribute within the vascular compartment. The radioactive decay allows measurement of RBC mass and survival via scintillation counting. No pharmacological effect; acts solely as a tracer.
Technetium-99m methylene diphosphonate (MDP) is a bone-seeking radiopharmaceutical. After intravenous injection, it adsorbs onto hydroxyapatite crystals in bone, with increased uptake in areas of high metabolic activity or blood flow, such as tumors or fractures. The technetium-99m emits gamma rays which are detected by a gamma camera for imaging.
Adult: 1-5 mCi (37-185 MBq) intravenously as a single dose for renal imaging. Dose depends on scan type and patient weight.
555–925 MBq (15–25 mCi) intravenously for bone scintigraphy; imaging performed 2–4 hours post-injection
None Documented
None Documented
Terminal half-life 70-90 minutes (prolonged in renal impairment to >12 hours).
Terminal elimination half-life is approximately 6-8 hours for the primary complex; minor radiochemical impurities may have longer half-lives
Primarily renal (50-70% as unchanged drug over 24 hours); minor biliary/fecal (10-20%).
Primarily renal (urinary excretion of 60-70% as unchanged drug within 24 hours, with 5-10% biliary excretion)
Category C
Category C
Diagnostic Radiopharmaceutical
Diagnostic Radiopharmaceutical